K

Longwood Capital logo

Longwood Capital

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Equity

Newleos Therapeutics logo
Newleos Therapeutics

Neuroscience • Clinical-stage

Novo Holdings logo
Longwood Fund logo
Goldman Sachs Alternatives logo
DCVC Bio logo

Newleos Therapeutics is a clinical-stage neuroscience company developing therapies for neuropsychiatric disorders, including anxiety and cognitive impairments, with a focus on first-in-class and best-in-class treatments.

Series A
$93.5M
02/13/2025
Article
Be Bio logo
Be Bio

Engineered B Cell Medicines • Therapeutic proteins

Nextech logo
Takeda Ventures logo
RA Capital Management logo
Longwood Fund logo

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Series C
$92M
01/15/2025
Article
Evommune logo
Evommune

Biotechnology • Clinical Development

RA Capital Management logo
Verition Fund Management logo
Symbiosis logo
RTW Investments logo

Evommune, Inc. is a biotechnology company focused on developing treatments for chronic inflammatory diseases.

Series C
$115M
10/31/2024
Article
Be Bio logo
Be Bio

Engineered B Cell Medicines • Therapeutic proteins

Takeda Ventures logo
RA Capital Management logo
Longwood Fund logo
Bristol Myers Squibb logo

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Equity
$82M
10/22/2024
Article
Lassen Therapeutics logo
Lassen Therapeutics

Clinical-stage biotech • IL-11 receptor

Longitude Capital logo
Longwood Capital logo
Frazier Life Sciences logo
Catalio Capital Management logo

Lassen Therapeutics is a clinical-stage biotech company developing novel treatments for fibro-inflammatory diseases and cancer, focusing on therapies targeting the IL-11 and IL-18 pathways.

Series B
$85M
12/19/2023
Article
Sitryx Therapeutics logo
Sitryx Therapeutics

Biopharmaceutical • Immunometabolism

GSK logo
SV Health Investors logo
Sofinnova Partners logo
Oxford Science Enterprises logo

Sitryx Therapeutics is a biopharmaceutical company that develops disease-modifying therapeutics for chronic autoimmune and inflammatory diseases by targeting and regulating cell metabolism.

Equity
$39M
09/27/2023
Article